Endocrine Abstracts

Background: Pituitary tumours (PT) are generally benign, but they can rarely show an aggressive behaviour, invade surrounding structures and/or grow/recur despite multimodal treatment, making their management extremely challenging. According to the latest guidelines, temozolomide (TMZ) can be an option after failure of standard therapies in aggressive PT, while little data are available on alternative approaches such as peptide receptor radionuclide therapy (PRRT). Herein we r...

The work-up of Differentiated Thyroid Cancer (DTC) patients includes thyroid surgery, thyroid remnant ablation (TRA) with 131-radioiodine and long life follow-up. 131I-post therapy whole body scan (pT-WBS) and thyroglobulin (Tg) are used in identifying metastatic patients. Some authors suggested to use post-surgical Tg (ps-Tg) values in deciding for or against TRA. The aim of our study was to verify the sensitivity and PPV of 131I-pT-WBS compared to serum Tg levels in detectin...

Background: PRRT, licensed for gastroenteropancreatic (GEP) NETs, has been used with somatostatin analogues such as lanreotide autogel (LAN). PRELUDE is the first international, multicentre retrospective study, with central radiology reading, to describe use of LAN with PRRT (LAN-PRRT) in advanced NETs.Methods: PRELUDE (NCT02788578) was an international, retrospective, non-comparative analysis of medical records of patients receiving LAN with 177Lu-DOTAT...

Background: Everolimus is the only approved drug for patients with advanced bronchopulmonary neuroendocrine tumors (NET), and there is an urgent unmet need for alternative treatments. Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SST)-positive lung NET. This study aims to investigate the clinical efficacy, safety, and patient-reported outcomes when 177Lu-edotreotide is used to treat...